Irritable Bowel Syndrome (IBS) is a common functional gastrointestinal disorder characterised by recurrent abdominal pain, bloating, and constipation and/or diarrhoea. As the underlying pathophysiology of the condition is complex and likely multifactorial, treatment options aim to manage the most distressing symptoms, such as laxatives for constipation, or loperamide for diarrhoea.

Clinical trials in patients with IBS have demonstrated the efficacy of two key probiotic strains for the reduction of the symptoms of IBS: Lactobacillus plantarum 299v and Lactobacillus rhamnosus GG. Biome IBS™ Probiotic contains these two key probiotic strains, each at a therapeutic dose supporting by the clinical research (10 Billion Live
Bacteria), and is indicated for the management of the symptoms of medically diagnosed Irritable Bowel Syndrome.